339 related articles for article (PubMed ID: 22886152)
21. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
22. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
23. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2012 Nov; 94(9):971-7. PubMed ID: 23073467
[TBL] [Abstract][Full Text] [Related]
24. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
Hauser IA; Schaeffeler E; Gauer S; Scheuermann EH; Wegner B; Gossmann J; Ackermann H; Seidl C; Hocher B; Zanger UM; Geiger H; Eichelbaum M; Schwab M
J Am Soc Nephrol; 2005 May; 16(5):1501-11. PubMed ID: 15772250
[TBL] [Abstract][Full Text] [Related]
25. Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt H; Danhof M; de Fijter H; Guchelaar HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):579-90. PubMed ID: 20354687
[TBL] [Abstract][Full Text] [Related]
26. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
27. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
Miao LY; Huang CR; Hou JQ; Qian MY
Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
29. Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients.
Xin HW; Liu HM; Li YQ; Huang H; Zhang L; Yu AR; Wu XC
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):497-503. PubMed ID: 24691060
[TBL] [Abstract][Full Text] [Related]
30. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Gervasini G; Garcia M; Macias RM; Cubero JJ; Caravaca F; Benitez J
Transpl Int; 2012 Apr; 25(4):471-80. PubMed ID: 22369694
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
[TBL] [Abstract][Full Text] [Related]
32. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.
Cattaneo D; Ruggenenti P; Baldelli S; Motterlini N; Gotti E; Sandrini S; Salvadori M; Segoloni G; Rigotti P; Donati D; Perico N; Remuzzi G;
J Am Soc Nephrol; 2009 Jun; 20(6):1404-15. PubMed ID: 19470683
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
34. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
35. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
36. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
von Ahsen N; Richter M; Grupp C; Ringe B; Oellerich M; Armstrong VW
Clin Chem; 2001 Jun; 47(6):1048-52. PubMed ID: 11375290
[TBL] [Abstract][Full Text] [Related]
37. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
Zhang X; Wang Z; Fan J; Liu G; Peng Z
Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
[TBL] [Abstract][Full Text] [Related]
38. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
39. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]